Evaluation and Treatment of Nausea and Vomiting in Adults

Tracy Johns, PharmD, MSMS, BCACP
Elizabeth Lawrence, MD, DABOM

American Family Physician. 2024;109(5):417-425.

Author disclosure: No relevant financial relationships.

Nausea and vomiting are common symptoms that can reduce quality of life and indicate life-threatening illness. Acute nausea and vomiting last up to 7 days. In the absence of alarm symptoms, they are typically treated symptomatically and without an extensive evaluation. Typical causes include gastroenteritis or other viral syndromes, foodborne illness, acute migraine headaches, vestibular disturbances, early pregnancy, and adverse effects of medication. Chronic nausea and vomiting last 4 weeks or longer and have a broad differential diagnosis. Causes can be gastrointestinal, infectious, metabolic, neurologic, psychiatric, or related to medications and toxins. A careful history of related factors is essential to guide the initial evaluation and narrow the differential diagnosis. These factors include associated symptoms, timing of onset and duration of symptoms, exacerbating or relieving factors, alarm symptoms, medication and substance use, relationship with recent food ingestion, and comorbidities. Nonpharmacologic management options include fluid and electrolyte replacement; small, frequent meals; and avoidance of trigger foods. Antiemetic drugs effectively reduce symptoms of acute nausea and vomiting, but chronic symptoms are often more challenging to treat. When a specific etiology is not identified, a serotonin antagonist or dopamine antagonist can be used. However, medications may also target the suspected cause of symptoms and the neurotransmitters involved in central and peripheral pathways of nausea and vomiting. Pharmacologic therapy should be used for the shortest time necessary to control symptoms.

Nausea and vomiting are common symptoms that lead patients to visit family physicians. Although usually self-limiting, they are significant causes of reduced quality of life and can indicate life-threatening illness.1,2

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating Comments
In the absence of alarm symptoms, acute nausea and vomiting should be treated symptomatically without an extensive evaluation.2,4,5 C Expert opinion, usual practice
Although serotonin antagonists are commonly used for acute gastroenteritis, the evidence to support their use in adults is limited.33,34 C Expert opinion, usual practice; systematic review of low-quality studies with insignificant results
Metoclopramide in combination with aspirin should be considered for nausea and vomiting caused by acute migraine.35 A Meta-analysis of good-quality randomized controlled trials
Antihistamines and anticholinergics can be used for motion sickness symptoms.41,42 B Meta-analysis of randomized controlled trials
Pyridoxine alone or combined with doxylamine is a first-line option for nausea and vomiting in pregnancy.21 C Consensus guidelines supported by systematic reviews with inconsistent findings

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

Nausea is the unpleasant sensation that vomiting might occur, whereas vomiting is the forceful expulsion of gastric contents from the mouth. Vomiting should be distinguished from regurgitation, the involuntary reflux of gastric contents into the esophagus and sometimes mouth without abdominal wall contractions, and from rumination, which is the voluntary, effortless flow of gastric contents into the mouth, where they are typically rechewed and swallowed. Retching involves spasmodic contractions with a closed glottis; it often precedes vomiting.3

TRACY JOHNS, PharmD, MSMS, BCACP, is the assistant director of the University of South Florida–Morton Plant Mease Family Medicine Residency Program, Clearwater, and an associate professor in the Department of Family Medicine at the University of South Florida Morsani College of Medicine, Tampa.

ELIZABETH LAWRENCE, MD, FAAFP, DABOM, is the program director of the University of South Florida–Morton Plant Mease Family Medicine Residency Program, and an associate professor in the Department of Family Medicine at the University of South Florida Morsani College of Medicine.

Address correspondence to Tracy Johns, PharmD, MSMS, BCACP, Turley Family Health Center, 807 N. Myrtle Ave., Clearwater, FL 33755 (tracy.johns@baycare.org). Reprints are not available from the authors.

Author disclosure: No relevant financial relationships.

  1. 1.Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3(6):543-552.
  2. 2.Quigley EM, Hasler WL, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterology. 2001;120(1):263-286.
  3. 3.Hasler WL, Chey WD. Nausea and vomiting. Gastroenterology. 2003;125(6):1860-1867.
  4. 4.Anderson WD, Strayer SM. Evaluation of nausea and vomiting: a case-based approach [published corrections appear in Am Fam Physician. 2013; 88(11): 728 and Am Fam Physician. 2014; 89(3): 152]. Am Fam Physician. 2013;88(6):371-379.
  5. 5.Tome J, Kamboj AK, Sweetser S. A practical 5-step approach to nausea and vomiting. Mayo Clin Proc. 2022;97(3):600-608.
  6. 6.Bányai K, Estes MK, Martella V, et al. Viral gastroenteritis. Lancet. 2018;392(10142):175-186.
  7. 7.American College of Radiology. ACR Appropriateness Criteria® right upper quadrant pain. Revised 2022. Accessed July 5, 2023. https://acsearch.acr.org/docs/69474/Narrative
  8. 8.American College of Radiology. ACR Appropriateness Criteria® acute pancreatitis. Revised 2019. Accessed July 5, 2023. https://acsearch.acr.org/docs/69468/Narrative
  9. 9.Chang KJ, Marin D, Kim DH, et al.; Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® suspected small-bowel obstruction. J Am Coll Radiol. 2020;17(5S):S305-S314.
  10. 10.Koop AH, Palmer WC, Stancampiano FF. Gastric outlet obstruction: a red flag, potentially manageable. Cleve Clin J Med. 2019;86(5):345-353.
  11. 11.Camilleri M, Sanders KM. Gastroparesis. Gastroenterology. 2022;162(1):68-87.e1.
  12. 12.Douglas AC, Wippold FJ, Broderick DF, et al. ACR Appropriateness Criteria headache. J Am Coll Radiol. 2014;11(7):657-667.
  13. 13.Scorza K, Williams A, Phillips JD, et al. Evaluation of nausea and vomiting. Am Fam Physician. 2007;76(1):76-84.
  14. 14.Frías JP, Davies MJ, Rosenstock J, et al.; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.
  15. 15.Aziz I, Palsson OS, Whitehead WE, et al. Epidemiology, clinical characteristics, and associations for Rome IV functional nausea and vomiting disorders in adults. Clin Gastroenterol Hepatol. 2019;17(5):878-886.
  16. 16.The Rome Foundation. Rome IV Criteria: B3. Nausea and vomiting disorders. Accessed June 17, 2023. https://theromefoundation.org/rome-iv/rome-iv-criteria/
  17. 17.Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373(19):1853-1863.
  18. 18.Sultan S, Altayar O, Siddique SM, et al.; AGA Institute. AGA Institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020;159(1):320-334.e27.
  19. 19.Switaj TL, Winter KJ, Christensen SR. Diagnosis and management of foodborne Illness. Am Fam Physician. 2015;92(5):358-365.
  20. 20.Lacy BE, Parkman HP, Camilleri M. Chronic nausea and vomiting: evaluation and treatment. Am J Gastroenterol. 2018;113(5):647-659.
  21. 21.Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin no. 189: Nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131(1):e15-e30.
  22. 22.Evans TH, Schiller LR. Chronic vestibular dysfunction as an unappreciated cause of chronic nausea and vomiting. Proc (Bayl Univ Med Cent). 2012;25(3):214-217.
  23. 23.Treasure J, Duarte TA, Schmidt U. Eating disorders. Lancet. 2020;395(10227):899-911.
  24. 24.Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380-1392.
  25. 25.Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241-249.
  26. 26.Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. J Med Toxicol. 2017;13(1):71-87.
  27. 27.Venkatesan T, Levinthal DJ, Li BUK, et al. Role of chronic cannabis use: cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome. Neurogastroenterol Motil. 2019;31(suppl2):e13606.
  28. 28.Flake ZA, Linn BS, Hornecker JR. Practical selection of antiemetics in the ambulatory setting. Am Fam Physician. 2015;91(5):293-296.
  29. 29.Heckroth M, Luckett RT, Moser C, et al. Nausea and vomiting in 2021: a comprehensive update. J Clin Gastroenterol. 2021;55(4):279-299.
  30. 30.Cangemi DJ, Kuo B. Practical perspectives in the treatment of nausea and vomiting. J Clin Gastroenterol. 2019;53(3):170-178.
  31. 31.Bonvanie IJ, Weghorst AA, Holtman GA, et al. Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial. Br J Gen Pract. 2021;71(711):e728-e735.
  32. 32.Fedorowicz Z, Jagannath VA, Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev. 2011(9):CD005506.
  33. 33.Furyk JS, Meek R, McKenzie S. Drug treatment of adults with nausea and vomiting in primary care. BMJ. 2014;349:g4714.
  34. 34.Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database Syst Rev. 2015(9):CD010106.
  35. 35.Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013(4):CD008041.
  36. 36.Ingrosso MR, Camilleri M, Tack J, et al. Efficacy and safety of drugs for gastroparesis: systematic review and network meta-analysis. Gastroenterology. 2023;164(4):642-654.
  37. 37.Lacy BE, Tack J, Gyawali CP. AGA clinical practice update on management of medically refractory gastroparesis: expert review. Clin Gastroenterol Hepatol. 2022;20(3):491-500.
  38. 38.Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol. 2022;117(8):1197-1220.
  39. 39.Murray-Brown F, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database Syst Rev. 2015(11):CD006271.
  40. 40.Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). Otolaryngol Head Neck Surg. 2017;156(3suppl):S1-S47.
  41. 41.Karrim N, Byrne R, Magula N, et al. Antihistamines for motion sickness. Cochrane Database Syst Rev. 2022(10):CD012715.
  42. 42.Spinks A, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011(6):CD002851.
  43. 43.Hu Y, Amoah AN, Zhang H, et al. Effect of ginger in the treatment of nausea and vomiting compared with vitamin B6 and placebo during pregnancy: a meta-analysis. J Matern Fetal Neonatal Med. 2022;35(1):187-196.
  44. 44.Chen L, Cai Z. The efficacy of ginger for the treatment of migraine: a meta-analysis of randomized controlled studies. Am J Emerg Med. 2021;46:567-571.
  45. 45.Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20(1):259.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.